Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Perivascular epithelioid cell tumour (PEComa), drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Malignancy cannot always be predicted from histology.
Resistance to mTOR inhibition eventually develops.
TFE3-rearranged PEComa lacks an effective drug.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Locally advanced unresectable or metastatic malignant PEComa
Objective response 39% (independent review), durable, enriched in TSC2-mutant tumours; FDA approval November 2021.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.